research The Effects of Estradiol, Androgens and the Selective Estrogen Modulators: Ospemifene, Raloxifene and Tamoxifen on Explant Cultures of Human Breast Tissue
Including androgens in hormone therapy may lower breast cancer risk.
Search
for
Sort by
Research
450-480 / 1000+ resultsresearch LB891 Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
research CDK4/6 plus aromatase inhibitor-induced alopecia in breast cancer patients.
Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.
research Association of breast cancer in men with exposure to 5-α reductase inhibitors: A RADAR report.
Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.
research Analysis of Data From Breast Diseases Treated With 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.
research Enhancement of Intermittent Androgen Ablation Therapy by Finasteride Administration in Animal Models
research Enhancement of Intermittent Androgen Ablation Therapy by Finasteride Administration in Animal Models
research Enhancement of Intermittent Androgen Ablation Therapy by Finasteride Administration in Animal Models
research The role of 5-alpha-reductase inhibitors in active surveillance
5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.
research Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.
research Incidence of alopecia from endocrine therapies in cancer
Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
research New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics
New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
research Aromatase deficiency in a male patient - Case report and review of the literature.
A male with aromatase deficiency improved bone health with estradiol treatment.
research 0478 Outcomes of oral dutasteride and oral minoxidil for treating endocrine therapy-induced alopecia from breast cancer treatment: A case series
research No elevated risk for osteoporosis or osteopenia among women with androgenetic or frontal fribrosing alopecia treated with 5-alpha reductase inhibitors: A retrospective TriNetX cohort study
5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.
research Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study
Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.
research Enhancement of Intermittent Androgen Ablation Therapy by Finasteride Administration in Animal Models
Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.
research Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α-reductase
Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
research Association of long-term 5α-reductase inhibitor use with survival in men with renal cell carcinoma: a nationwide population-based cohort study
Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.
research Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity
A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.
research 5-Alpha Reductase Inhibitors in Prostate Cancer: From Clinical Trials to Clinical Practice
5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
research Patient-reported outcomes of adverse events after perioperative chemotherapy for breast cancer: A prospective observational study
Some side effects of breast cancer chemotherapy last longer than others, and patient feedback can help improve care.
research Male Breast Cancer and 5α-Reductase Inhibitors Finasteride and Dutasteride
Using finasteride or dutasteride does not increase the risk of male breast cancer.
research Onychomatricoma with classic features: Case report and review of the literature
Hair loss is a common side effect of hormone treatments for cancer.
research Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.
research Association of prior 5-α-reductase inhibitor exposure with ICI benefit in metastatic RCC: Multicentre cohort with single-cell immune profiling.
Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
research Gender-Affirming Hormone Therapy for Transgender Females
Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.
research Questions and Answers
Doctors recommend postoperative radiation for male breast cancer, advise against testosterone for vasomotor symptoms post-adrenalectomy, suggest non-hormonal treatments for atrophic vaginitis after mastectomy, note no specific treatment for anticoagulant-induced hair loss, and call for more research on silicosis from silicon carbide exposure.
research Multiple drugs
Some breast cancer treatments caused long-term hair loss in women, similar to a condition called alopecia areata.
research Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.